The role of radiation for pancreatic adenocarcinoma
Abstract. Pancreatic cancer is an aggressive malignancy with a high recurrence rate even after curative-intent resection. Improvements in survival have not been achieved in the last 25 years thus highlighting the need for effective multimodal treatment strategies. The role of radiation therapy for p...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2020-06-01
|
| Series: | Journal of Pancreatology |
| Online Access: | http://journals.lww.com/10.1097/JP9.0000000000000045 |
| _version_ | 1818726823606878208 |
|---|---|
| author | Adriana C. Gamboa, MD Rachel M. Lee, MD, MSPH Shishir K. Maithel, MD |
| author_facet | Adriana C. Gamboa, MD Rachel M. Lee, MD, MSPH Shishir K. Maithel, MD |
| author_sort | Adriana C. Gamboa, MD |
| collection | DOAJ |
| description | Abstract. Pancreatic cancer is an aggressive malignancy with a high recurrence rate even after curative-intent resection. Improvements in survival have not been achieved in the last 25 years thus highlighting the need for effective multimodal treatment strategies. The role of radiation therapy for pancreatic cancer remains ill-defined due to historical lack of a standard definition of resectability, and the use of antiquated radiation delivery techniques and chemotherapy regimens. Current level I data regarding neoadjuvant chemoradiotherapy for resectable and borderline resectable pancreatic adenocarcinoma (PDAC) are limited to 2 randomized controlled trials and several retrospective studies and suggest that it may lead to an increased likelihood of a margin-negative resection and certainly allows for improved patient selection for pancreaticoduodenectomy when compared to upfront surgery. In the adjuvant setting, data are similarly lacking but suggest that chemoradiotherapy may be beneficial for patients at high risk of locoregional recurrence. Here we review existing data regarding the role of radiation in PDAC. |
| first_indexed | 2024-12-17T22:04:20Z |
| format | Article |
| id | doaj.art-5d18fe0ee88445309d5e35a4ca976bd1 |
| institution | Directory Open Access Journal |
| issn | 2096-5664 2577-3577 |
| language | English |
| last_indexed | 2024-12-17T22:04:20Z |
| publishDate | 2020-06-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Journal of Pancreatology |
| spelling | doaj.art-5d18fe0ee88445309d5e35a4ca976bd12022-12-21T21:30:54ZengWolters Kluwer Health/LWWJournal of Pancreatology2096-56642577-35772020-06-0132728010.1097/JP9.0000000000000045202006000-00003The role of radiation for pancreatic adenocarcinomaAdriana C. Gamboa, MD0Rachel M. Lee, MD, MSPH1Shishir K. Maithel, MD2Division of Surgical Oncology, Winship Cancer Institute, Department of Surgery, Emory University, Atlanta, USADivision of Surgical Oncology, Winship Cancer Institute, Department of Surgery, Emory University, Atlanta, USADivision of Surgical Oncology, Winship Cancer Institute, Department of Surgery, Emory University, Atlanta, USAAbstract. Pancreatic cancer is an aggressive malignancy with a high recurrence rate even after curative-intent resection. Improvements in survival have not been achieved in the last 25 years thus highlighting the need for effective multimodal treatment strategies. The role of radiation therapy for pancreatic cancer remains ill-defined due to historical lack of a standard definition of resectability, and the use of antiquated radiation delivery techniques and chemotherapy regimens. Current level I data regarding neoadjuvant chemoradiotherapy for resectable and borderline resectable pancreatic adenocarcinoma (PDAC) are limited to 2 randomized controlled trials and several retrospective studies and suggest that it may lead to an increased likelihood of a margin-negative resection and certainly allows for improved patient selection for pancreaticoduodenectomy when compared to upfront surgery. In the adjuvant setting, data are similarly lacking but suggest that chemoradiotherapy may be beneficial for patients at high risk of locoregional recurrence. Here we review existing data regarding the role of radiation in PDAC.http://journals.lww.com/10.1097/JP9.0000000000000045 |
| spellingShingle | Adriana C. Gamboa, MD Rachel M. Lee, MD, MSPH Shishir K. Maithel, MD The role of radiation for pancreatic adenocarcinoma Journal of Pancreatology |
| title | The role of radiation for pancreatic adenocarcinoma |
| title_full | The role of radiation for pancreatic adenocarcinoma |
| title_fullStr | The role of radiation for pancreatic adenocarcinoma |
| title_full_unstemmed | The role of radiation for pancreatic adenocarcinoma |
| title_short | The role of radiation for pancreatic adenocarcinoma |
| title_sort | role of radiation for pancreatic adenocarcinoma |
| url | http://journals.lww.com/10.1097/JP9.0000000000000045 |
| work_keys_str_mv | AT adrianacgamboamd theroleofradiationforpancreaticadenocarcinoma AT rachelmleemdmsph theroleofradiationforpancreaticadenocarcinoma AT shishirkmaithelmd theroleofradiationforpancreaticadenocarcinoma AT adrianacgamboamd roleofradiationforpancreaticadenocarcinoma AT rachelmleemdmsph roleofradiationforpancreaticadenocarcinoma AT shishirkmaithelmd roleofradiationforpancreaticadenocarcinoma |